Trial Profile
Open-label Multicentre Confirmatory Study of Efficacy and Safety of S 95005 (TAS-102) in Patients With Metastatic Colorectal Cancer Who Are Refractory or Intolerant to Standard Chemotherapies
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 15 May 2023
Price :
$35
*
At a glance
- Drugs Tipiracil/trifluridine (Primary)
- Indications Adenocarcinoma; Colorectal cancer
- Focus Therapeutic Use
- Sponsors Servier
- 20 Dec 2018 Status changed from active, no longer recruiting to completed.
- 20 Aug 2018 Planned End Date changed from 28 Sep 2018 to 31 Dec 2018.
- 10 Apr 2018 Planned End Date changed from 7 May 2018 to 28 Sep 2018.